Praxis surges after filing two drug applications with FDA breakthrough status
Biotech company's $20B pipeline potential fuels analyst optimism as it transitions to commercial stage
Praxis Precision Medicines shares climbed 17% over the past month after the biotechnology company submitted two new drug applications to the US Food and Drug Administration, marking a critical milestone as it transitions from clinical-stage development to commercial operations.
The Cambridge, Massachusetts-based company filed NDAs for ulixacaltamide to treat essential tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, rare genetic conditions that cause severe seizures in infants and young children. Both treatments received FDA Breakthrough Therapy Designation, a status reserved for therapies that show substantial improvement over existing treatments for serious or life-threatening conditions.
Essential tremor, which affects an estimated 7 million Americans, currently has limited treatment options, with many patients relying on off-label use of medications approved for other conditions. The FDA granted Breakthrough Therapy Designation to ulixacaltamide in December 2025, potentially accelerating its review timeline. Relutrigine also secured Orphan Drug Designation, providing seven years of market exclusivity upon approval.
Wall Street analysts have responded enthusiastically to the filings, driving price targets sharply higher. The stock, currently trading at $329, has already delivered a 356% return over the past 12 months, reflecting growing confidence in Praxis's pipeline. According to analyst consensus data, 14 of 15 covering analysts rate the shares a Buy, with an average price target of approximately $573, implying roughly 74% upside from current levels.
The most bullish forecasts have come from analysts at H.C. Wainwright, which lifted its target to $1,245 from $340, calling ulixacaltamide "transformative" and projecting peak sales of $6.8 billion for relutrigine alone. Guggenheim raised its target to $800 from $760, citing expert feedback suggesting the essential tremor market opportunity exceeds $15 billion. Piper Sandler upgraded its target to $1,200 from $450, maintaining an Overweight rating.
Praxis estimates its late-stage portfolio of four assets—ulixacaltamide, relutrigine, vormatrigine, and elsunersen—collectively represents peak revenue potential exceeding $20 billion. Topline results for vormatrigine and elsunersen are expected in the first half of 2026, with additional NDA submissions anticipated within the next two years.
The company strengthened its financial position to support the commercial transition through two capital raises. Cash, cash equivalents, and marketable securities totaled $926.1 million as of December 31, 2025, up from $469.5 million a year earlier. Including $621.2 million in net proceeds from a January 2026 public offering, Praxis expects its cash position of approximately $1.55 billion to fund operations into 2028, providing substantial runway through the commercial launch period.
Research and development spending increased significantly in 2025, rising to $267.1 million from $152.4 million the previous year, as the company advanced its pipeline toward commercialization. The net loss widened to $303.3 million in 2025 from $182.8 million in 2024, reflecting the investment required to prepare for potential product launches.
Commercial preparations for ulixacaltamide and relutrigine are underway and will accelerate throughout 2026, Praxis stated in its corporate update. The company anticipates transitioning into a commercial company pending positive FDA reviews of the submitted NDAs.
Praxis faces execution risks as it navigates the regulatory approval process and builds commercial infrastructure from scratch. The stock's dramatic rally—shares are trading 25 times above their 200-day moving average—suggests substantial expectations are already priced in. Some analysts have noted that valuation concerns could emerge if regulatory setbacks occur or if commercialization proves more challenging than anticipated.
Upcoming catalysts include topline results from the POWER1 Phase 3 study of vormatrigine for focal onset seizures in the second quarter of 2026, and data from the EMBRAVE Phase 1/2 study of elsunersen for early-seizure-onset SCN2A developmental and epileptic encephalopathy, also expected in the first half of the year. The EMERALD study for relutrigine in broader developmental and epileptic encephalopathies is expected to be fully enrolled in the second half of 2026, potentially supporting a supplemental NDA submission in 2027 if results are positive.